The Effects of Angle Kappa on Clinical Outcomes With the PanOptix Intraocular Lens

Exclusion Criteria

• •1. Severe preoperative ocular pathology
• •2. Subjects who require a higher toric power than the one available (TFNT60).
• •3. Uncontrolled diabetes.
• •4. Use of any systemic or topical drug known to interfere with visual performance.
• •5. Contact lens use during the active treatment portion of the trial.
• •6. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
• •7. Clinically significant corneal dystrophy
• •8. History of chronic intraocular inflammation.
• •9. History of retinal detachment.
• •10. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
• •11. Previous ocular surgery.
• •12. Severe dry eye
• •13. Pupil abnormalities
• •14. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
• •15. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
• •16. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.